# Miami Classification for Probe-Based Confocal Laser Endomicroscopy

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1055/s-0030-1256632</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:12601541">http://nrs.harvard.edu/urn-3:HUL.InstRepos:12601541</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Miami classification for probe-based confocal laser endomicroscopy

An essential element for any new advanced imaging technology is standardization of indications, terminology, categorization of images, and research priorities. In this review, we propose a state-of-the-art classification system for normal and pathological states in gastrointestinal disease using probe-based confocal laser endomicroscopy (pCLE). The Miami classification system is based on a consensus of pCLE users reached during a meeting held in Miami, Florida, in February 2009.

Introduction

Probe-based confocal laser endomicroscopy (pCLE) and its related technology, endoscope-based CLE (eCLE), are rapidly emerging methods of imaging with the potential to fundamentally change the role of biopsy in gastrointestinal endoscopy. Since the advent of endoscopic imaging, biopsy has been used to confirm or exclude pathology. Although highly valuable, biopsy is expensive, and there can be delays between endoscopy and a “confirmed” diagnosis and/or treatment. In addition, although the risks associated with biopsy are small, the number of biopsies performed worldwide is enormous, and therefore risk becomes an important consideration.

CLE methods offer the potential to decrease or possibly eliminate the need for some biopsies and to directly guide treatment of circumscribed lesions, such as colorectal polyps, in real time. CLE can also help to avoid biopsy, or if biopsy is necessary, to direct it more efficiently in areas of very low diagnostic yield, such as in surveillance of Barrett’s esophagus, ulcerative colitis, and indeterminate bile duct strictures. Although it is still premature to determine the exact roles of pCLE in each gastrointestinal condition, it is essential to establish standards for image interpretation at an early stage of development.

We determined that a unique classification system was needed for pCLE due to the significant technical differences compared with eCLE (smaller field of view, fixed depth), as well as the fact that many of the eCLE images published in the literature have used acriflavine (a nuclear stain) and are not comparable to pCLE images, which are almost exclusively obtained with fluorescein-only contrast.

Methods for development of criteria

A group of experts was assembled based on their early experience with pCLE imaging in a variety of gastrointestinal conditions. As pCLE technology is new, there was a limited number of individuals with significant expertise in each field prior to February 2009, and a limited number of clinical trials on which to establish standards. Thus the standards were largely based on expert opinion, and consensus development. In general, each group developed criteria based on the following algorithm:

- acquisition and review of unended images with pathological confirmation
- description of features unique to each histological state (e.g. metaplasia, neoplasia)
- pilot testing of accuracy in a small sample of cases blinded to the histology
- where available validation, including interobserver agreement, in a large sample with multiple users.

The Miami consensus conference involved presentation of standard images and specific features of each condition, together with group discussion and consensus development. Following the conference, a report was drafted by the lead co-author for each section, and the final criteria and manuscript were approved by all co-authors.
General techniques for pCLE

Probe technology
The confocal microscope used in pCLE captures microscopic images of untreated in vivo tissue. The microscope uses focused laser light of a defined wavelength and passes it through a confocal aperture. Images are then reconstructed in two dimensions.

For pCLE (Cellvizio by Mauna Kea Technologies, Paris, France), both the laser scanning unit and light source are outside the body. The laser beam is transported via flexible confocal miniprobes and a distal lens sequentially scans it through a bundle of more than 10000 optical fibers. Confocal miniprobes are flexible, with diameters ranging from 0.9 mm to 2.5 mm. Therefore, this system may be introduced through the working channels of endoscopes (Fig. 1).

Image acquisition, processing, and display
pCLE image data are collected at 12 frames per second, enabling video quality and direct visualization of blood on a single erythrocyte scale. Depending on the probe used, the field of view ranges from 240 μm to 600 μm (one-quarter to one-half of a millimeter). The clinical system consists of a miniprobe connected to a laser scanning unit that is connected to a standard personal computer for image data processing and display (Fig. 1). Images are reviewed with a specially designed software package (Cellvizio Viewer), allowing image correction and stabilization.

Contrast agents, dose, and safety
Different dyes, such as fluorescein or cresyl violet, have been used for contrast enhancement [1–3]. Cresyl violet may only be administered topically, whereas fluorescein may also be injected intravenously. Fluorescein is the current substance of choice because it is relatively inexpensive, non-mutagenic, enables higher imaging depth than topically administered contrast agents, and it has been safely used for decades in ophthalmology [4]. Injection of 1.0–5.0 mL of a 10% solution enables visualization of individual cells with strong contrast of the capillary network. This is the current standard dosage in most settings. Hence, dynamic images of blood flow and supply are possible, making it a useful tool for detection of neo-angiogenesis [5].

The exact mechanism by which neoplastic cells appear dark is poorly understood. It is clear that fluorescence is not seen within these cells. Several mechanisms have been proposed including lack of fluorescein uptake, more rapid excretion from the cell [1], or greater leakage into the lamina propria, thus increasing the relative darkness of the epithelial cells [6].

Endoscopic techniques for high-quality image acquisition of mucosal disease
The keys to obtaining high quality images are timing, positioning, and stability. Gradual changes in image quality occur in a time-dependant fashion after intravenous injection of fluorescein. Optimal contrast is obtained within the first 10 min after injection, but good quality images can be acquired for a further 30–60 min [3]. However, bleeding can impair image quality; therefore, the probe should be placed gently in contact with the tissue in order to avoid trauma, particularly if friability is expected, such as in neoplasms or severely inflamed tissue. As with other imaging methods, it is best to complete pCLE imaging in a region before biopsy or tissue removal is completed.

If possible, the probe should be perpendicular to the mucosa, rather than parallel to it. This can be difficult if the lumen is very...
narrow, as in biliary strictures. In these circumstances, a cholangioscopic approach or biliary catheter with side hole or bendable tip might help to maneuver the probe into the wall of the bile duct. Movements caused by the examiner or the patient (breathing or peristalsis) can significantly impair positioning of the probe and cause artifacts. Using a clear 4-mm cap on the tip of the endoscope and applying gentle suction helps to hold the probe in position. This approach can be very helpful for the imaging of Barrett’s esophagus or small colonic polyps. Other methods to improve the match between pCLE imaging sites and biopsy sites include the use of a dual-channel endoscope (with pCLE probe in one channel and biopsy forceps in the other) or the use of cautery marking with argon plasma coagulation or coagulating (“hot”) biopsy forceps. The most useful methods for research studies require highly precise matching of image and biopsy locations.

Applications of pCLE
The main focus of pCLE has been the detection and classification of neoplasia in Barrett’s esophagus and colonic polyps. However, several other conditions have also been studied to a lesser extent and others are just beginning to be studied. Table 1 lists these potential applications in order of the current extent of evidence.

Comparison of eCLE and pCLE
Both endoscopy- and probe-based methods of CLE have advantages and disadvantages. eCLE offers a wider field of view, the ability to vary the depth of imaging from 0–250 μm compared with a fixed imaging plane (approximately 50 μm below the surface of GastroFlex), and slightly better lateral resolution (approximately 0.8 μm vs. 1 μm). Advantages of pCLE are the versatility of a probe system that can be passed via any endoscope, or even needles, and more rapid image acquisition (12 frames per second vs. 0.8–1.6 frames/s), which allows imaging of in vivo blood flow. Both systems have inherent limitations compared with wide field endoscopic methods, including the very small field of view, cost of the technology, learning curve, and extra time needed to view the images during endoscopy.

Barrett’s esophagus
Surveillance guidelines for the management of patients with Barrett’s esophagus call for target biopsies from visible lesions, followed by random four-quadrant biopsies every 2 cm [7]. This practice is time-consuming, costly, and challenging as sampling is not always accurate. Detailed analysis of esophagectomy specimens from patients with Barrett’s esophagus has revealed that areas of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and cancer are extremely focal and occupy extremely small areas within the Barrett’s segment [8]. To overcome these shortcomings, advanced endoscopic techniques including pCLE have been developed to maximize the positive and negative predictive values of dysplasia detection in patients with Barrett’s esophagus. CLE is a highly targeted technology that may be useful for lesion classification. However, other technologies, such as narrow band imaging (NBI), autofluorescence imaging (AFI), and chromoendoscopy are needed as “broad-base surface imaging” techniques to initially detect and localize suspicious areas.

In patients with Barrett’s esophagus, CLE captures very high resolution and detailed images including glandular architecture, crypts, columnar cells, goblet cells, and capillaries with red blood cells. In patients with a columnar-lined esophagus, the diagnosis of Barrett’s esophagus can be confirmed by identifying and confirming the presence of intestinal metaplasia, which is characterized by the presence of goblet cells. Furthermore, based on preliminary data, CLE also has high accuracy in detecting HGD or cancer.

Classification of CLE images as non-dysplastic or dysplastic has been evaluated in a few pilot studies using varying criteria [3,4]. An initial study by Kesslich et al. evaluated criteria for gastric type, intestinal and neoplastic epithelium, based on cellular and vascular architecture details of CLE images [9]. Images that demonstrate regular-shaped capillaries visible only in deeper mucosa, regular columnar-lined epithelium with round glandular openings, and typical cobblestone appearance, were suggestive of gastric-type foveolar epithelium; whereas, regular capillaries that were present in upper and deeper parts of the mucosal layer along with identification of dark (“non-refractile”) mucin in goblet cells in columnar-lined mucosa, were diagnosed as intestinal metaplasia (non-dysplastic Barrett’s esophagus). The diagnosis of dysplasia/cancer was based on the identification of irregular capillaries in upper and deeper parts of the mucosal layer (suggestive of neo-angiogenesis) with black cells that had irregular apical and distal borders and shapes on confocal images. Using these criteria, Barretts-associated dysplasia could be predicted with a sensitivity of 93% and a specificity of 98%. Compared with gastric metaplasia, Barrett’s metaplasia could be predicted with a sensitivity of 98% and a specificity of 94%.

In another recent study, Pohl et al. tested the diagnostic characteristics of pCLE for the detection of invisible Barrett’s-associated dysplasia [10]. The investigators initially established pCLE criteria for neoplastic Barrett’s esophagus including dark, irregularly thickened epithelial borders, dilated irregular vessels, and in adenocarcinoma, disorganization of villiform structures and crypts and dark columnar cells. These criteria were established from 95 biopsies (15 patients) and then tested prospectively in 201 biopsies (23 patients). pCLE videos were also assessed by two endoscopists and the inter-observer agreement was tested. The overall sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 80%, 94%, 44%, and 99%, respectively, with good inter-observer agreement (Kappa = 0.6). A wide group of expert endoscopists evaluated these criteria and validated them as reliable and reproducible. Using a standardized set of 20 video images of dysplastic [11] and non-dysplastic Barrett’s sites [10], Wallace et al. reported preliminary sensitivity of 88% and specificity of 96% and good inter-observer agreement (agreement rate 86%, Kappa = 0.72) [12]. These pCLE criteria have now been tested and validated in a large, prospective, multi-center, randomized controlled trial (DON

---

**Table 1** Potential applications of (probe-based) confocal laser endomicroscopy.

<table>
<thead>
<tr>
<th>Well-evaluated areas</th>
<th>Barrett’s esophagus guide to biopsy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Areas of early exploration</td>
<td>Inflammatory bowel disease dysplasia</td>
</tr>
<tr>
<td></td>
<td>Biliary strictures</td>
</tr>
<tr>
<td></td>
<td>Duodenal neoplasia</td>
</tr>
<tr>
<td>Experimental areas</td>
<td>Solid and cystic tumor imaging</td>
</tr>
<tr>
<td></td>
<td>Gastric neoplasia</td>
</tr>
</tbody>
</table>

---

BIOPCE trial) [13]. This trial used independent, blinded endoscopists to perform tandem endoscopic procedures to evaluate the sensitivity and specificity of pCLE in addition to white light endoscopy for the detection of HGD and early adenocarcinoma in Barrett’s esophagus. Final data presented at Digestive Disease Week 2010 (1–6 May, New Orleans, Louisiana, USA) included 874 sites (120 with high grade intra-epithelial neoplasia [HGIEN] or cancer) in 101 patients (31 with HGIEN or cancer). On a per patient basis, the combination of pCLE with high-definition white light endoscopy was significantly more accurate than endoscopy alone (sensitivity/specificity of pCLE + endoscopy 95%/67% vs. endoscopy 85%/71%). The addition of pCLE to endoscopy and NBI was also more accurate than endoscopy + NBI alone (sensitivity/specificity of pCLE + endoscopy + NBI 100%/56% vs. endoscopy + NBI 97%/56%). Using pCLE to guide biopsy in patients with Barrett’s esophagus, where only suspicious sites are biopsied would result in a 76% reduction in biopsies with no HGIEN patients missed, although 24% of sites would have been missed. If pCLE was
used to guide biopsy, and four-quadrant random plus targeted biopsies were taken only in those patients with at least one abnormal lesion on pCLE, then this would result in a 39% reduction in biopsies with no missed sites or patients. In summary, CLE criteria for dysplastic and non-dysplastic Barrett’s esophagus have been established and tested in pilot studies. Their validation in a large multicenter study is ongoing and eagerly awaited. It is likely that these criteria will continue to be refined as larger studies are conducted.

- Fig. 2 shows the current pCLE-based classification system with image and histological examples.

### Biliary disease

Accurate diagnosis and staging of pancreatobiliary cancers is important for both prognosis and for guiding therapy; however, it remains challenging to differentiate benign from malignant strictures despite advanced imaging and tissue sampling methods. Up to 15% of all suspected cholangiocarcinomas originating from the liver hilum reveal benign histology following surgery [11]. Conversely, only 20% of hilar cancers are resectable at the time of diagnosis, and the rate of R0 resections is unfavorably low [14]. This diagnostic dilemma holds true despite the introduction of tissue sampling methods such as biopsy, brush cytology, or fine-needle aspiration (FNA) cytology through endoscopic retrograde cholangiopancreatography (ERCP) or endoscopic ultrasound (EUS). The best outcomes are obtained when several sampling techniques are combined, but even then remain suboptimal. Rösch et al. reported that combining brush cytology with forceps biopsy yielded a sensitivity of 54% and a specificity of 100% [15]. If endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was added to these methods, then the sensitivity increased to 71%, but specificity was still 100%. Ponchon et al. reported that combining brush cytology and forceps biopsy yielded a sensitivity of 63% and a specificity of 97% [16]. Schoeff et al. showed that the combination of brush cytology and biopsy yielded a sensitivity of 70.4% and a specificity of 100% [17]. Hence, there is a critical need to improve the diagnostic accuracy of pancreatobiliary pathology, thereby enabling a more tailored approach for patients and minimizing unnecessary operations.

pCLE that provides in vivo microscopic imaging of tissues in real time can be introduced through the working channel of an ERCP catheter or cholangioscope, in order to access and visualize the pancreatobiliary ductal system during the procedure. Meining et al. reported on a series of 14 patients with biliary strictures that were examined by pCLE via cholangioscopy, and compared the modality to standard endoscopic tissue sampling [18]. pCLE imaging of the biliary structure was feasible in all cases. The presence of irregular, dilated (“angiogenic”) vessels was the laser microscopic hallmark for prediction of neoplasia, with an accuracy of 86%, sensitivity of 83%, and specificity of 88%. The respective numbers for standard histopathology were 79%, 50%, and 100%. The mean signal-to-noise-ratio of endomicroscopic images acquired from malignant strictures differed significantly from those of benign origin (1.8 ± 0.8 vs. 2.6 ± 1.0; P = 0.005). As a preliminary conclusion, pCLE could considerably increase sensitivity for the detection of pancreatobiliary neoplasia, and therefore, represents a promising diagnostic approach. Large multicentric studies are ongoing.

To date, pCLE examination during ERCP procedures has been selectively applied to patients with signs, symptoms, or test results that indicate malignancy or indeterminate pancreatobiliary structure. The technique for pancreatobiliary pCLE is straightforward. ERCP is performed in accordance with the standard of care, and the stricture is accessed either with an ERCP catheter or a cholangioscope. The pCLE probe is introduced through the lumen of the catheter or the working channel of the cholangioscope, and the lesion of interest is targeted for microscopic imaging using fluoroscopy or endoscopic guidance. The pCLE probe is positioned at the site(s) of suspected pathology immediately following intravenous injection of fluorescein sodium. Real-time in vivo sequences are acquired and stored for review, usually immediately after a site of interest has been imaged.

The choice of the optimal access delivery system for pCLE during ERCP (catheter vs. cholangioscopic access and delivery) is currently being investigated. In part, the decision depends on the endoscopy unit resources and operator preference. Initial experience with pCLE during ERCP procedures shows that real-time sequences can be obtained with either delivery method [19]. A variety of catheter models have been used in conjunction with the miniprobe (see Table 2). Access through the SpyGlass system (Boston Scientific, Natick, Massachusetts, USA), Olympus cholangioscopes (Olympus Corp., Tokyo, Japan), and Storz prototype cholangioscope (Karl Storz GmbH, Tuttingen, Germany) are all also possible.

The Cellvizio CholangioFlex probe is dedicated to pCLE during ERCP procedures, and it has been miniaturized to an external diameter of 0.94 mm, in order to meet the constraints of intraduc- tal access devices. The probe fits inside lumens of 1.2 mm in diameter, has a field of view of 325 μm, a lateral resolution of 3.5 μm, and an imaging depth of 40–70 μm below the tissue surface. Specific pCLE image interpretation criteria are under development.

- Fig. 3 shows typical pCLE findings in normal bile ducts and biliary cancer.

### Colorectal disease

Several advanced imaging techniques may play a role in facilitating both the detection of dysplasia in the colon, as well as classification between neoplastic and non-neoplastic lesions during colonoscopy. CLE can provide imaging of single cells, making it unsuitable for the detection of lesions in the colon; however, it has

---

**Table 2** List of endoscopic retrograde cholangiopancreatography (ERCP) devices that have been used successfully and can accommodate the CholangioFlex probe (Cellvizio, Mauna Kea Technologies, Paris). The list is based on clinical experiences of current users of probe-based confocal laser endomicroscopy and does not represent a recommendation from the manufacturers. Differences in size and diameter of the working channel might impair the compatibility in some cases.

<table>
<thead>
<tr>
<th>Device name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cotton® Graduated Dilation Catheter 17.0</td>
<td>Cook Medical</td>
</tr>
<tr>
<td>OASIS® One Action Stent Introduction System</td>
<td>Cook Medical</td>
</tr>
<tr>
<td>Memory Dormia basket (Ref MSB_35_2X4 Memory)</td>
<td>Cook Medical</td>
</tr>
<tr>
<td>Howell Biliary Introducer (H-BIN)</td>
<td>Cook Medical</td>
</tr>
<tr>
<td>Geenen® Graduated Dilation Catheter</td>
<td>Cook Medical</td>
</tr>
<tr>
<td>Swing Tip™ ERCP cannula</td>
<td>Olympus Medical</td>
</tr>
</tbody>
</table>

* Cook Medical, Inc., Bloomington, Indiana, USA; Olympus Medical Systems, Tokyo, Japan
Chromoendoscopy, NBI, and a combination of NBI and AFI called endoscopic trimodal imaging (ETMI) may predict histology based on the Kudo pit pattern, vascular pattern intensity (VPI), and color. All of these techniques have a rather low specificity. CLE, however, has the potential to provide real-time conventional histopathology with a very high specificity.

Ideally, a method with a high detection rate of neoplastic lesions (usually at the cost of lower specificity) should be combined with a method of optimal differentiation of all detected lesions. Such combinations can be made by pan-colonic chromoendoscopy or autofluorescence as a “red flag technique” used in conjunction with endoscopic pit pattern analysis and CLE for the differentiation of detected lesions.

**Colorectal polyps**

The detection of neoplastic lesions has been significantly improved by chromoendoscopy compared with conventional colonoscopy, whereas NBI only showed an improvement during the learning phase [22,23]. In one randomized study ETMI (white light + NBI + AFI) did not result in an increased adenoma detection rate [24]. Conventional endoscopy has limited ability to discriminate adenomatous from non-adenomatous colorectal polyps. In daily practice, all identified lesions are routinely removed and sent for histopathology. This approach results in substantial increase of endoscopic workload, additional pathology costs, and increase in potential complications. If CLE could reliably predict histology, then it could increase cost-effectiveness and efficiency considerably. This is a concept suggested by several prominent colonoscopists [25].

However, the decision to decide to leave a polyp in situ and not send it for pathology requires high accuracy and particularly high NPV of the imaging method. Chromoendoscopy, NBI, and AFI have shown unacceptable test characteristics for this purpose, with accuracies of 91%, 89%, and 79%, respectively [24]. CLE has shown high agreement with true histopathology. In earlier feasibility studies, Kiesslich et al. demonstrated an accuracy of 99% with the integrated system, whereas, feasibility studies with the probe-based system reached an accuracy of 82–92% [2,20,21].

A prospective study of CLE in polypt differentiation has been published. Sanduleanu et al. performed a prospective study using chromoendoscopy-guided CLE with the integrated system to evaluate differential features of adenomatous and non-adenomatous colorectal polyps, resulting in an accuracy of 96% [26]. Acriflavine was used in conjunction with fluorescein, enabling discrimination of HGD from LGD, with an accuracy of 97%.

Another large prospective double-blind trial compared pCLE with NBI and Fujinon Intelligence Color Enhancement (FICE, Fujinon, Fort Wayne, New Jersey, USA), for polyp classification. Buchner et al. demonstrated that pCLE was superior to digital chromoendoscopy methods; however, it was primarily superior to FICE without significant improvement over NBI. The sensitivity of pCLE for neoplastic polyps was 91% and specificity was 76%, compared with virtual chromoendoscopy (NBI and FICE), which had a sensitivity of 77% and a specificity of 71% [27].

This same group evaluated the learning curve for pCLE for colorectal polyps and found that new users rapidly acquired the ability to interpret pCLE images with accuracy similar to that of highly experienced experts. New users were able to interpret images with an accuracy of 93% after reading at least 35 cases. This study did not assess the accuracy of new users during live video endoscopies, which may require more experience [28].

Further prospective studies and data are eagerly awaited that examine the cost-effectiveness of CLE for colorectal polyps with both the integrated as well as the probe-based system. Data on the assessment of degree of dysplasia, inter-observer variability, and learning curve are also anticipated. At the same time, other applications for the use of the CLE system (e.g. early detection of adenomatous tissue at a scar at the resection site of a polyp), should be explored.

Fig. 4 shows the criteria for pCLE classification of colorectal polyps.

---

**Fig. 3** Bile duct. a Normal appearing bile duct with fine, reticular gray pattern (thin black arrow). b Biliary cancer. Note dark, irregular structures (thin black arrow) interspersed with bright areas of tortuous dilated blood vessel (thick white arrow).
Fig. 4 Colon. a Graphic showing colonic mucosa progressing from normal crypts (left side) to dysplastic crypts and villiform structures (right side). b Panels showing probe-based confocal laser endomicroscopy images and hematoxylin and eosin images of colonic disease.

**Normal colon**
- Round crypt structures
- Dark goblet cells (arrow)
- Regular, narrow vessels surrounding crypts (block arrow)

**Hyperplastic polyp**
- Crypts with slit or stellate openings (pits)
- Bright non-thickened, uniform epithelium
- Dark goblet* cells (thin arrow)
- Small vessels (block arrow)

**Adenoma**
- Irregular or villiform structures (note even "tubular" adenoma may have villiform structure on pCLE)
- Dark, irregularly thickened epithelium
- Decreased goblet cells

**Adenocarcinoma**
- Disorganized villiform or lack of structure
- Dark, irregularly thickened epithelium (thin arrow)
- Dilated vessels (block arrow on H&E)

**Colitis**
- Crypt fusion and distortion (arrow)
- Bright epithelium
- Dilated, prominent branching vessels (block arrow)
Ulcerative colitis

As patients with ulcerative colitis have an increased risk of developing dysplasia, guidelines recommend colonoscopic surveillance including targeted biopsies of suspicious lesions and multiple (40) random biopsies. However, the yield for dysplasia on random biopsy is very low, and standard endoscopic imaging cannot identify most neoplastic lesions. Several randomized studies have shown that targeting biopsies with chromoendoscopy significantly increases dysplasia detection rates in patients with longstanding ulcerative colitis [29,30]. In one randomized study, ETMI also increased dysplasia detection rates but NBI did not [31,32].

Using initial chromoscopy followed by directed eCLE combines the strengths of both techniques in ulcerative colitis. While pan-chromoscopy facilitates the detection of flat lesions in ulcerative colitis, subsequent targeted confocal endomicroscopy can be used to differentiate between neoplastic and non-neoplastic tissue, thus obviating the need for targeted biopsies of lesions that appeared non-neoplastic. This can also be used to possibly differentiate random biopsies in chromo-negative areas. By using this diagnostic approach in a randomized study in 161 patients, Kieslich et al. detected almost five times more dysplastic lesions than conventional colonoscopy with random biopsies [33].

Using the integrated CLE system, Hurlstone et al. demonstrated a high overall accuracy of 97% for in vivo differentiation of adenoma-like mass (ALM) and dysplasia-associated lesion or mass (DALM) in patients with chronic ulcerative colitis [34]. Case reports using the pCLE system suggest it may also be used to identify DALM lesions [35]. This technique could provide gastroenterologists with important information for selecting patients who are suitable for immediate endoscopic resection vs. referral for pan-proctocolectomy. Recent studies also suggest that CLE may be a valuable tool for the grading of colitis and detection of microscopic colitis in regions of the colon without visible inflammation [36].

All of these studies have been performed with the integrated CLE system. Studies with the probe-based CLE system are currently underway. Further data from non-tertiary referral centers and from investigation of the learning curve and inter-observer agreement in patients with chronic ulcerative colitis are necessary before implementation of chromoscopy-guided CLE can be recommended in daily practice.

Fig. 4 shows the criteria for pCLE classification of colitis and associated dysplasia.
Gastric diseases

To date there are limited data exploring application of confocal imaging to the stomach. There is a potential role for CLE in the discrimination of indeterminate gastric lesions in countries where gastric cancer is more common and screening endoscopies are performed. In two studies from Japan, CLE demonstrated typical features of dysplasia such as enlarged and increased numbers of nuclei [37]. CLE had an accuracy of 94–96% for diagnosis of malignancy among 27 patients with early gastric cancer, when compared directly with histological biopsies [38]. Other potential but unexplored applications include distinction between adenomatous and fundic gland polyps. Fig. 5 shows typical pCLE images of normal gastric mucosa, inflammation, and dysplasia.

Duodenal diseases

As with the stomach, there are limited data on duodenal applications. Given the frequency of biopsies performed to detect celiac disease in patients with signs or symptoms of malabsorption, this would be a valuable role for CLE, especially given the relatively low yield of endoscopic biopsy. Two small case reports have suggested that confocal endomicroscopy can detect villous atrophy and increased intra-epithelial cellularity (presumed to be lymphocytes) [39,40]. In a recent study of 17 patients with celiac disease and 14 control individuals, CLE detected typical celiac changes of villous atrophy and crypt hypertrophy. The accuracy of CLE was excellent, with sensitivity of 94% and specificity of 92% [41].

Detection of duodenal adenomas is also a potentially valuable role for CLE. The risk of ampullary and non-ampullary duodenal cancer is substantially elevated in familial adenomatous polyposis, leading to recommendations for routine duodenal surveillance and ampullary biopsy [42]. A downside of biopsy of the ampulla is the risk of inducing acute pancreatitis [43], such that non-biopsy methods would be preferable. Preliminary data from Shalid et al. at the Mayo Clinic (Florida, USA) suggest that pCLE may be highly accurate for the detection of both ampullary and non-ampullary adenomas, although more data are needed [44]. The features of dysplasia are typical of those in other gastrointestinal sites including dark, irregular epithelium (Fig. 6).

Research priorities

To determine the value of these potential roles and explore new ones, critical research is needed, including in the following areas.

- Determine precise estimates of accuracy compared with current standard endoscopic methods in colon polyps, Barrett’s esophagus, ulcerative colitis, biliary cancer, and gastric dysplasia.
- Determine the reliability of pCLE in a community setting.
- Assess the ability to guide immediate endoscopic therapy in Barrett’s-associated dysplasia, colorectal endoscopic mucosal resection, and polypectomy.
- Determine preliminary accuracy and reliability in bile duct cancer.
- Assess the cost-effectiveness of pCLE compared with standard competing technologies including biopsy.
- Develop improved methods for image stabilization.
- Develop improved methods for image interpretation systems including computer-aided diagnosis.
- Assess the feasibility and accuracy of intratumoral and intracystic CLE via needles (nCLE).

Summary and future directions

pCLE has the potential to directly guide endoscopic therapy of dysplasia and significantly reduce the number of non-targeted (random) biopsies. Application of this technology has the further advantage of visualizing a dynamic process on a microscopic level for monitoring and determination of blood flow in various conditions. Further miniaturization of the probe will imply new indications, such as placing the miniprobe through an FNA needle for EUS-guided examinations of solid or cystic tumors and for interventions. In addition, integrating new biological fluorophores such as fluorescein-bound peptides will potentially enable the precise detection of dysplasia in vivo and guide subsequent intervention during the same procedure.

Competing interests: Dr Meining receives research funding from Mauna Kea Technologies and is co-patent holder of Cholangio-Flex probes. Dr Sharma receives funding from Barrx Inc., Cook Medical, Olympus, and Takeda. Dr Wallace receives research funding from Olympus, Cook Medical, Boston Scientific, Mauna Kea Technologies, and American BioOptics. Dr Dekker receives research funding from Olympus and has equipment on loan from Olympus and Mauna Kea Technologies. The other authors have nothing to declare.

Institutions
1 Department of Gastroenterology, Mayo Clinic, Jacksonville, Florida, USA
2 Division of Surgical Pathology and Gastrointestinal Pathology Service, Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
3 Division of Gastroenterology and Hepatology, University of Colorado Denver, Denver, Colorado, USA
4 Academic Medical Center, Amsterdam, The Netherlands
5 Kansas University Medical Center and Department of Veterans Affairs Medical Center, Kansas City, Kansas, USA
6 Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

Acknowledgment

We thank Ms Alice McKinney of the Mayo Clinic Jacksonville Graphic Department for creation of the graphic representations of tissue histology, Ms Kelly Viola of the Mayo Clinic for editorial support, and Ms Anne Osdoit of Mauna Kea Technologies for providing confocal images and confirming technical aspects of the pCLE system.

References